ArticleAntimicrobial agents and chemotherapy2019
Synergistic Effect of Colistin Combined with PFK-158 against Colistin-Resistant Enterobacteriaceae.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Colistin Resistance in Bacteria: Current Updates on Mechanism of Action and Combating Strategies.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- PFK-158 enhances colistin efficacy against resistantFrontiers in veterinary science · 2026Article
- PAM-1: an antimicrobial peptide with promise against ceftazidime-avibactam resistantFrontiers in microbiology · 2024Article
- Resveratrol Increases Sensitivity of Clinical Colistin-Resistant Pseudomonas aeruginosa to ColistinMicrobiology spectrum · 2023Article
- Antibacterial and Antivirulence Activities of Acetate, Zinc Oxide Nanoparticles, and Vitamin C Against E. coli O157:H7 and P. aeruginosa.Current microbiology · 2023Article
- Article
- Synergistic effect and antibiofilm activity of the antimicrobial peptide K11 with conventional antibiotics against multidrug-resistant and extensively drug-resistantFrontiers in cellular and infection microbiology · 2023Article
- Synergistic Activity of Tetrandrine and Colistin againstAntibiotics (Basel, Switzerland) · 2022Article
- Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.Microbiology spectrum · 2022Article
- Synergistic Antimicrobial Effect of Antimicrobial Peptides CATH-1, CATH-3, and PMAP-36 With Erythromycin Against Bacterial Pathogens.Frontiers in microbiology · 2022Article
- Colistin Resistance and Management of Drug Resistant Infections.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Review
- Global epidemiology, genetic environment, risk factors and therapeutic prospects ofFrontiers in cellular and infection microbiology · 2022Review
- ML364 exerts the broad-spectrum antivirulence effect by interfering with the bacterial quorum sensing system.Frontiers in microbiology · 2022Article
- A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-ResistantFrontiers in cellular and infection microbiology · 2021Article
- Quercetin Rejuvenates Sensitization of Colistin-ResistantFrontiers in chemistry · 2021Article
- Combined With Mefloquine, Resurrect Colistin Active in Colistin-ResistantFrontiers in microbiology · 2021Article
- Synergistic Activity and Biofilm Formation Effect of Colistin Combined with PFK-158 Against Colistin-Resistant Gram-Negative Bacteria.Infection and drug resistance · 2021Article
- Polymyxins and Bacterial Membranes: A Review of Antibacterial Activity and Mechanisms of Resistance.Membranes · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As increasing numbers of colistin-resistant bacteria emerge, new therapies are urgently needed to treat infections caused by these pathogens. The discovery of new combination therapies is one important way to solve such problems. Here, we report that the antitumor drug PFK-158 and its analogs PFK-015 and 3PO can exert synergistic effects with colistin against colistin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.